[en] In clinical practice we often meet with impairment of elimination organs in cancer patients before or during the administration of systemic antineoplastic therapy. Given limited available data from clinical trials, the treatment of this patients group resembles a serious problem. It is mainly on issues of higher risk of toxicity, but also possible changes in effectiveness of administered drugs. The article is devoted to the problems of administration of systemic chemotherapy in patients with liver dysfunction. (author)